Limitations of Antifungal Prophylaxis in Preventing Invasive Surgical Site Infections After Liver Transplant Surgery

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2024 Feb 1

PMID 38299818

Authors

M Carugati

S Arif

M E Yarrington

L Y King

M Harris

K Evans

A S Barbas

D L Sudan

J R Perfect

R A Miller

B D Alexander

Affiliations

Soon will be listed here.

Abstract

Invasive primary surgical site infections (IP-SSIs) are a common complication of liver transplantation, and targeted antifungal prophylaxis is an efficient strategy to limit their occurrence. We performed a retrospective single-center cohort study among adult single liver transplant recipients at Duke University Hospital in the period between 1 January 2015 and 31 December 2020. The study aimed to determine the rate of IP-SSI according to the peri-transplant antifungal prophylaxis received. Of 470 adult single liver transplant recipients, 53 (11.3%) received micafungin prophylaxis, 100 (21.3%) received fluconazole prophylaxis, and 317 (67.4%) did not receive systemic antifungal prophylaxis in the peri-transplant period. Ten IP-SSIs occurred among 5 of 53 (9.4%) micafungin recipients, 1 of 100 (1.0%) fluconazole recipients, and 4 of 317 (1.3%) recipients who did not receive antifungal prophylaxis. Our study highlights the limitations of antifungal prophylaxis in preventing invasive IP-SSI after liver transplant surgery. We hypothesize that pathogen, host, and pharmacokinetic-related factors contributed to the occurrence of IP-SSI despite antifungal prophylaxis. Our study reinforces the need for a risk-based, multi-pronged approach to fungal prevention, including targeted antifungal administration in patients with risks for invasive candidiasis and close monitoring, especially among patients with surgically complex procedures, with timely control of surgical leaks.

References

Alexander B, Johnson M, Pfeiffer C, Jimenez-Ortigosa C, Catania J, Booker R . Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013; 56(12):1724-32. PMC: 3658363. DOI: 10.1093/cid/cit136. View

Carugati M, Arif S, Sudan D, Collins B, Haney J, Schroder J . Epidemiology of surgical site infections after solid organ transplants in the period 2015-2019: A single-center retrospective cohort study. Am J Transplant. 2022; 22(12):3021-3030. DOI: 10.1111/ajt.17189. View

Breitkopf R, Treml B, Senoner T, Bukumiric Z, Rajsic S . Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients. J Fungi (Basel). 2023; 9(2). PMC: 9961099. DOI: 10.3390/jof9020272. View

Aslam S, Rotstein C . Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13623. DOI: 10.1111/ctr.13623. View

Saliba F, Pascher A, Cointault O, Laterre P, Cervera C, De Waele J . Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2014; 60(7):997-1006. PMC: 4357288. DOI: 10.1093/cid/ciu1128. View

Andes D, Safdar N, Baddley J, Alexander B, Brumble L, Freifeld A . The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis. 2016; 18(6):921-931. DOI: 10.1111/tid.12613. View

Vergidis P, Clancy C, Shields R, Park S, Wildfeuer B, Simmons R . Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One. 2016; 11(4):e0153247. PMC: 4849645. DOI: 10.1371/journal.pone.0153247. View

Welte R, Eller P, Lorenz I, Joannidis M, Bellmann R . Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients. Antimicrob Agents Chemother. 2018; 62(4). PMC: 5913985. DOI: 10.1128/AAC.02326-17. View

Pfeiffer C, Garcia-Effron G, Zaas A, Perfect J, Perlin D, Alexander B . Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010; 48(7):2373-80. PMC: 2897493. DOI: 10.1128/JCM.02390-09. View

10.

Cornely O, Hoenigl M, Lass-Florl C, Chen S, Kontoyiannis D, Morrissey C . Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019; 62(9):716-729. PMC: 6692208. DOI: 10.1111/myc.12960. View

11.

Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S . Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011; 17(5):731-4. DOI: 10.1007/s10156-011-0240-3. View

12.

Baker A, Maziarz E, Arnold C, Johnson M, Workman A, Reynolds J . Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. Clin Infect Dis. 2019; 70(1):30-39. PMC: 6912154. DOI: 10.1093/cid/ciz156. View

13.

Fortun J, Muriel A, Martin-Davila P, Montejo M, Len O, Torre-Cisneros J . Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. Liver Transpl. 2015; 22(4):427-35. DOI: 10.1002/lt.24391. View

14.

Howard S, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A . Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother. 2011; 55(10):4880-7. PMC: 3186993. DOI: 10.1128/AAC.00621-11. View

15.

Zhao Y, Prideaux B, Nagasaki Y, Lee M, Chen P, Blanc L . Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrob Agents Chemother. 2017; 61(10). PMC: 5610477. DOI: 10.1128/AAC.01009-17. View

16.

Winston D, Limaye A, Pelletier S, Safdar N, Morris M, Meneses K . Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014; 14(12):2758-64. DOI: 10.1111/ajt.12963. View

17.

Grau S, Luque S, Campillo N, Samso E, Rodriguez U, Garcia-Bernedo C . Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015; 70(10):2854-61. DOI: 10.1093/jac/dkv173. View

18.

Viehman J, Clancy C, Clarke L, Shields R, Silveira F, Kwak E . Surgical Site Infections After Liver Transplantation: Emergence of Multidrug-Resistant Bacteria and Implications for Prophylaxis and Treatment Strategies. Transplantation. 2016; 100(10):2107-14. DOI: 10.1097/TP.0000000000001356. View